Follow the Dollar: Measuring who profits from a brand-name prescription

Originally posted in Drug Channels on Thursday, October 13, 2016 by Adam J. Fein, Ph.D.   Now, here’s something I hope you’ll really like! I recently collaborated with Julie Appleby at Kaiser Health ... read more

Oncology Biosimilars: Opportunity or Not?

F. Randy Vogenberg, PhD, RPh   Martha M. Rumore, PharmD, JD, MS, LLM, FAPhA   Originally published in VBCC - April 2016, Vol 7, No 3 - Employers’ Perspective   The United States has the largest biologic drugs market and high p... read more

Employers Engaged in Benefit Design Innovation: Long-Term Trends in a 2015 National Survey

Originally posted 12/28/2015 on American Health & Drug Benefits    In the past 5 years, there has been a large increase in the number of employers focused on effective ways to manage the rising cost of specialty drugs. At the same time, emplo... read more

Will Employers Favor Private Exchanges Over Coverage Sponsorship?

Originally posted 10/17/14 on The Health Affairs Blog   By Brian Klepper   Over the past couple years, health care exchanges probably have consumed more of corporate benefits managers’ time and psychic energy than any other topic. An outsta... read more

Mirror, Mirror on the Wall, 2014 Update: How the U.S. Health Care System Compares Internationally

Tom Emerick   Thus reads the headline in a report recently published by the Commonwealth Fund.  The short answer is we compare poorly. Says the report, “The United States health care system is the most expensive in the world, but this repo... read more